Patents and New Product Development in the Pharmaceutical and Biotechnology Industries
Download full text from publisher
CitationsCitations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
- Panattoni, Laura E., 2011. "The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms," Journal of Health Economics, Elsevier, vol. 30(1), pages 126-145, January.
More about this item
NEP fieldsThis paper has been announced in the following NEP Reports:
- NEP-ALL-2003-11-03 (All new papers)
- NEP-COM-2003-11-03 (Industrial Competition)
- NEP-HEA-2003-11-03 (Health Economics)
- NEP-INO-2003-11-03 (Innovation)
- NEP-MFD-2003-11-03 (Microfinance)
- NEP-TID-2003-11-03 (Technology & Industrial Dynamics)
StatisticsAccess and download statistics
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cla:levarc:618897000000000661. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (David K. Levine). General contact details of provider: http://www.dklevine.com/ .
We have no references for this item. You can help adding them by using this form .